alks-10q_20190630.htm
Alkermes plc. 0001520262 false --12-31 false Large Accelerated Filer Q2 981007018 true true true true P10Y P56D P5Y P1Y P5Y P5Y P3Y 981007018 P12Y P13Y P12Y 0001520262 2019-01-01 2019-06-30 xbrli:shares 0001520262 2019-07-22 iso4217:USD 0001520262 2019-06-30 0001520262 2018-12-31 iso4217:USD xbrli:shares 0001520262 alks:ManufacturedProductAndRoyaltyMember 2019-04-01 2019-06-30 0001520262 alks:ManufacturedProductAndRoyaltyMember 2018-04-01 2018-06-30 0001520262 alks:ManufacturedProductAndRoyaltyMember 2019-01-01 2019-06-30 0001520262 alks:ManufacturedProductAndRoyaltyMember 2018-01-01 2018-06-30 0001520262 us-gaap:ProductMember 2019-04-01 2019-06-30 0001520262 us-gaap:ProductMember 2018-04-01 2018-06-30 0001520262 us-gaap:ProductMember 2019-01-01 2019-06-30 0001520262 us-gaap:ProductMember 2018-01-01 2018-06-30 0001520262 alks:ResearchAndDevelopmentMember 2019-04-01 2019-06-30 0001520262 alks:ResearchAndDevelopmentMember 2018-04-01 2018-06-30 0001520262 alks:ResearchAndDevelopmentMember 2019-01-01 2019-06-30 0001520262 alks:ResearchAndDevelopmentMember 2018-01-01 2018-06-30 0001520262 us-gaap:LicenseMember 2019-04-01 2019-06-30 0001520262 us-gaap:LicenseMember 2018-04-01 2018-06-30 0001520262 us-gaap:LicenseMember 2019-01-01 2019-06-30 0001520262 us-gaap:LicenseMember 2018-01-01 2018-06-30 0001520262 2019-04-01 2019-06-30 0001520262 2018-04-01 2018-06-30 0001520262 2018-01-01 2018-06-30 0001520262 2017-12-31 0001520262 2018-06-30 0001520262 us-gaap:CommonStockMember 2018-12-31 0001520262 us-gaap:AdditionalPaidInCapitalMember 2018-12-31 0001520262 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2018-12-31 0001520262 us-gaap:RetainedEarningsMember 2018-12-31 0001520262 us-gaap:TreasuryStockMember 2018-12-31 0001520262 us-gaap:CommonStockMember 2019-01-01 2019-03-31 0001520262 us-gaap:AdditionalPaidInCapitalMember 2019-01-01 2019-03-31 0001520262 2019-01-01 2019-03-31 0001520262 us-gaap:TreasuryStockMember 2019-01-01 2019-03-31 0001520262 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2019-01-01 2019-03-31 0001520262 us-gaap:RetainedEarningsMember 2019-01-01 2019-03-31 0001520262 us-gaap:CommonStockMember 2019-03-31 0001520262 us-gaap:AdditionalPaidInCapitalMember 2019-03-31 0001520262 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2019-03-31 0001520262 us-gaap:RetainedEarningsMember 2019-03-31 0001520262 us-gaap:TreasuryStockMember 2019-03-31 0001520262 2019-03-31 0001520262 us-gaap:CommonStockMember 2019-04-01 2019-06-30 0001520262 us-gaap:AdditionalPaidInCapitalMember 2019-04-01 2019-06-30 0001520262 us-gaap:TreasuryStockMember 2019-04-01 2019-06-30 0001520262 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2019-04-01 2019-06-30 0001520262 us-gaap:RetainedEarningsMember 2019-04-01 2019-06-30 0001520262 us-gaap:CommonStockMember 2019-06-30 0001520262 us-gaap:AdditionalPaidInCapitalMember 2019-06-30 0001520262 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2019-06-30 0001520262 us-gaap:RetainedEarningsMember 2019-06-30 0001520262 us-gaap:TreasuryStockMember 2019-06-30 0001520262 2018-01-01 2018-03-31 0001520262 us-gaap:CommonStockMember 2017-12-31 0001520262 us-gaap:AdditionalPaidInCapitalMember 2017-12-31 0001520262 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2017-12-31 0001520262 us-gaap:RetainedEarningsMember 2017-12-31 0001520262 us-gaap:TreasuryStockMember 2017-12-31 0001520262 us-gaap:CommonStockMember 2018-01-01 2018-03-31 0001520262 us-gaap:AdditionalPaidInCapitalMember 2018-01-01 2018-03-31 0001520262 us-gaap:TreasuryStockMember 2018-01-01 2018-03-31 0001520262 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2018-01-01 2018-03-31 0001520262 us-gaap:RetainedEarningsMember 2018-01-01 2018-03-31 0001520262 us-gaap:CommonStockMember 2018-03-31 0001520262 us-gaap:AdditionalPaidInCapitalMember 2018-03-31 0001520262 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2018-03-31 0001520262 us-gaap:RetainedEarningsMember 2018-03-31 0001520262 us-gaap:TreasuryStockMember 2018-03-31 0001520262 2018-03-31 0001520262 us-gaap:CommonStockMember 2018-04-01 2018-06-30 0001520262 us-gaap:AdditionalPaidInCapitalMember 2018-04-01 2018-06-30 0001520262 us-gaap:TreasuryStockMember 2018-04-01 2018-06-30 0001520262 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2018-04-01 2018-06-30 0001520262 us-gaap:RetainedEarningsMember 2018-04-01 2018-06-30 0001520262 us-gaap:CommonStockMember 2018-06-30 0001520262 us-gaap:AdditionalPaidInCapitalMember 2018-06-30 0001520262 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2018-06-30 0001520262 us-gaap:RetainedEarningsMember 2018-06-30 0001520262 us-gaap:TreasuryStockMember 2018-06-30 alks:segment 0001520262 2019-01-01 0001520262 alks:RoyaltyRevenueMember alks:InvegaSustennaOrXeplionAndInvegaTrinzaMember 2019-04-01 2019-06-30 0001520262 alks:ManufacturedProductAndRoyaltyMember alks:InvegaSustennaOrXeplionAndInvegaTrinzaMember 2019-04-01 2019-06-30 0001520262 alks:RoyaltyRevenueMember alks:InvegaSustennaOrXeplionAndInvegaTrinzaMember 2019-01-01 2019-06-30 0001520262 alks:ManufacturedProductAndRoyaltyMember alks:InvegaSustennaOrXeplionAndInvegaTrinzaMember 2019-01-01 2019-06-30 0001520262 alks:ManufacturingRevenueMember alks:RISPERDALCONSTAMember 2019-04-01 2019-06-30 0001520262 alks:RoyaltyRevenueMember alks:RISPERDALCONSTAMember 2019-04-01 2019-06-30 0001520262 alks:ManufacturedProductAndRoyaltyMember alks:RISPERDALCONSTAMember 2019-04-01 2019-06-30 0001520262 alks:ManufacturingRevenueMember alks:RISPERDALCONSTAMember 2019-01-01 2019-06-30 0001520262 alks:RoyaltyRevenueMember alks:RISPERDALCONSTAMember 2019-01-01 2019-06-30 0001520262 alks:ManufacturedProductAndRoyaltyMember alks:RISPERDALCONSTAMember 2019-01-01 2019-06-30 0001520262 alks:ManufacturingRevenueMember alks:AMPYRAOrFAMPYRAMember 2019-04-01 2019-06-30 0001520262 alks:RoyaltyRevenueMember alks:AMPYRAOrFAMPYRAMember 2019-04-01 2019-06-30 0001520262 alks:ManufacturedProductAndRoyaltyMember alks:AMPYRAOrFAMPYRAMember 2019-04-01 2019-06-30 0001520262 alks:ManufacturingRevenueMember alks:AMPYRAOrFAMPYRAMember 2019-01-01 2019-06-30 0001520262 alks:RoyaltyRevenueMember alks:AMPYRAOrFAMPYRAMember 2019-01-01 2019-06-30 0001520262 alks:ManufacturedProductAndRoyaltyMember alks:AMPYRAOrFAMPYRAMember 2019-01-01 2019-06-30 0001520262 alks:ManufacturingRevenueMember alks:OtherProductsAndServicesMember 2019-04-01 2019-06-30 0001520262 alks:RoyaltyRevenueMember alks:OtherProductsAndServicesMember 2019-04-01 2019-06-30 0001520262 alks:ManufacturedProductAndRoyaltyMember alks:OtherProductsAndServicesMember 2019-04-01 2019-06-30 0001520262 alks:ManufacturingRevenueMember alks:OtherProductsAndServicesMember 2019-01-01 2019-06-30 0001520262 alks:RoyaltyRevenueMember alks:OtherProductsAndServicesMember 2019-01-01 2019-06-30 0001520262 alks:ManufacturedProductAndRoyaltyMember alks:OtherProductsAndServicesMember 2019-01-01 2019-06-30 0001520262 alks:ManufacturingRevenueMember 2019-04-01 2019-06-30 0001520262 alks:RoyaltyRevenueMember 2019-04-01 2019-06-30 0001520262 alks:ManufacturedProductAndRoyaltyMember 2019-04-01 2019-06-30 0001520262 alks:ManufacturingRevenueMember 2019-01-01 2019-06-30 0001520262 alks:RoyaltyRevenueMember 2019-01-01 2019-06-30 0001520262 alks:ManufacturedProductAndRoyaltyMember 2019-01-01 2019-06-30 0001520262 alks:RoyaltyRevenueMember alks:InvegaSustennaOrXeplionAndInvegaTrinzaMember 2018-04-01 2018-06-30 0001520262 alks:ManufacturedProductAndRoyaltyMember alks:InvegaSustennaOrXeplionAndInvegaTrinzaMember 2018-04-01 2018-06-30 0001520262 alks:RoyaltyRevenueMember alks:InvegaSustennaOrXeplionAndInvegaTrinzaMember 2018-01-01 2018-06-30 0001520262 alks:ManufacturedProductAndRoyaltyMember alks:InvegaSustennaOrXeplionAndInvegaTrinzaMember 2018-01-01 2018-06-30 0001520262 alks:ManufacturingRevenueMember alks:RISPERDALCONSTAMember 2018-04-01 2018-06-30 0001520262 alks:RoyaltyRevenueMember alks:RISPERDALCONSTAMember 2018-04-01 2018-06-30 0001520262 alks:ManufacturedProductAndRoyaltyMember alks:RISPERDALCONSTAMember 2018-04-01 2018-06-30 0001520262 alks:ManufacturingRevenueMember alks:RISPERDALCONSTAMember 2018-01-01 2018-06-30 0001520262 alks:RoyaltyRevenueMember alks:RISPERDALCONSTAMember 2018-01-01 2018-06-30 0001520262 alks:ManufacturedProductAndRoyaltyMember alks:RISPERDALCONSTAMember 2018-01-01 2018-06-30 0001520262 alks:ManufacturingRevenueMember alks:AMPYRAOrFAMPYRAMember 2018-04-01 2018-06-30 0001520262 alks:RoyaltyRevenueMember alks:AMPYRAOrFAMPYRAMember 2018-04-01 2018-06-30 0001520262 alks:ManufacturedProductAndRoyaltyMember alks:AMPYRAOrFAMPYRAMember 2018-04-01 2018-06-30 0001520262 alks:ManufacturingRevenueMember alks:AMPYRAOrFAMPYRAMember 2018-01-01 2018-06-30 0001520262 alks:RoyaltyRevenueMember alks:AMPYRAOrFAMPYRAMember 2018-01-01 2018-06-30 0001520262 alks:ManufacturedProductAndRoyaltyMember alks:AMPYRAOrFAMPYRAMember 2018-01-01 2018-06-30 0001520262 alks:ManufacturingRevenueMember alks:OtherProductsAndServicesMember 2018-04-01 2018-06-30 0001520262 alks:RoyaltyRevenueMember alks:OtherProductsAndServicesMember 2018-04-01 2018-06-30 0001520262 alks:ManufacturedProductAndRoyaltyMember alks:OtherProductsAndServicesMember 2018-04-01 2018-06-30 0001520262 alks:ManufacturingRevenueMember alks:OtherProductsAndServicesMember 2018-01-01 2018-06-30 0001520262 alks:RoyaltyRevenueMember alks:OtherProductsAndServicesMember 2018-01-01 2018-06-30 0001520262 alks:ManufacturedProductAndRoyaltyMember alks:OtherProductsAndServicesMember 2018-01-01 2018-06-30 0001520262 alks:ManufacturingRevenueMember 2018-04-01 2018-06-30 0001520262 alks:RoyaltyRevenueMember 2018-04-01 2018-06-30 0001520262 alks:ManufacturedProductAndRoyaltyMember 2018-04-01 2018-06-30 0001520262 alks:ManufacturingRevenueMember 2018-01-01 2018-06-30 0001520262 alks:RoyaltyRevenueMember 2018-01-01 2018-06-30 0001520262 alks:ManufacturedProductAndRoyaltyMember 2018-01-01 2018-06-30 0001520262 alks:VivitrolMember 2019-04-01 2019-06-30 0001520262 alks:VivitrolMember 2018-04-01 2018-06-30 0001520262 alks:VivitrolMember 2019-01-01 2019-06-30 0001520262 alks:VivitrolMember 2018-01-01 2018-06-30 0001520262 alks:AristadaMember 2019-04-01 2019-06-30 0001520262 alks:AristadaMember 2018-04-01 2018-06-30 0001520262 alks:AristadaMember 2019-01-01 2019-06-30 0001520262 alks:AristadaMember 2018-01-01 2018-06-30 0001520262 alks:BiogenMember 2019-04-01 2019-06-30 0001520262 alks:BiogenMember 2019-01-01 2019-06-30 0001520262 alks:BiogenMember 2018-04-01 2018-06-30 0001520262 alks:BiogenMember 2018-01-01 2018-06-30 0001520262 alks:ResearchAndDevelopmentMember alks:BiogenMember us-gaap:ScenarioForecastMember 2021-01-01 2021-12-31 0001520262 srt:MinimumMember 2019-01-01 2019-06-30 0001520262 srt:MaximumMember 2019-01-01 2019-06-30 0001520262 us-gaap:ShortTermInvestmentsMember us-gaap:CorporateDebtSecuritiesMember 2019-06-30 0001520262 us-gaap:ShortTermInvestmentsMember us-gaap:USGovernmentAgenciesDebtSecuritiesMember 2019-06-30 0001520262 us-gaap:ShortTermInvestmentsMember us-gaap:ForeignGovernmentDebtSecuritiesMember 2019-06-30 0001520262 us-gaap:ShortTermInvestmentsMember 2019-06-30 0001520262 alks:LongTermInvestmentsMember us-gaap:CorporateDebtSecuritiesMember 2019-06-30 0001520262 alks:LongTermInvestmentsMember us-gaap:USGovernmentAgenciesDebtSecuritiesMember 2019-06-30 0001520262 alks:LongTermInvestmentsMember us-gaap:ForeignGovernmentDebtSecuritiesMember 2019-06-30 0001520262 alks:LongTermInvestmentsMember 2019-06-30 0001520262 us-gaap:ShortTermInvestmentsMember us-gaap:CorporateDebtSecuritiesMember 2018-12-31 0001520262 us-gaap:ShortTermInvestmentsMember us-gaap:USGovernmentAgenciesDebtSecuritiesMember 2018-12-31 0001520262 us-gaap:ShortTermInvestmentsMember us-gaap:ForeignGovernmentDebtSecuritiesMember 2018-12-31 0001520262 us-gaap:ShortTermInvestmentsMember 2018-12-31 0001520262 alks:LongTermInvestmentsMember us-gaap:CorporateDebtSecuritiesMember 2018-12-31 0001520262 alks:LongTermInvestmentsMember us-gaap:USGovernmentAgenciesDebtSecuritiesMember 2018-12-31 0001520262 alks:LongTermInvestmentsMember us-gaap:ForeignGovernmentDebtSecuritiesMember 2018-12-31 0001520262 alks:LongTermInvestmentsMember 2018-12-31 0001520262 alks:LongTermInvestmentsMember us-gaap:CertificatesOfDepositMember 2019-06-30 0001520262 alks:FixedTermDepositAccountMember alks:LongTermInvestmentsMember 2019-06-30 0001520262 alks:LongTermInvestmentsMember us-gaap:CertificatesOfDepositMember 2018-12-31 0001520262 alks:FixedTermDepositAccountMember alks:LongTermInvestmentsMember 2018-12-31 iso4217:EUR 0001520262 srt:MaximumMember alks:FountainHealthcarePartnersIiLpOfIrelandMember 2014-05-31 0001520262 us-gaap:OtherAssetsMember alks:FountainHealthcarePartnersIiLpOfIrelandMember 2019-06-30 xbrli:pure 0001520262 alks:FountainHealthcarePartnersIiLpOfIrelandMember 2019-06-30 0001520262 alks:FountainHealthcarePartnersIiLpOfIrelandMember 2019-04-01 2019-06-30 0001520262 alks:FountainHealthcarePartnersIiLpOfIrelandMember 2019-01-01 2019-06-30 0001520262 alks:FountainHealthcarePartnersIiLpOfIrelandMember 2018-04-01 2018-06-30 0001520262 alks:FountainHealthcarePartnersIiLpOfIrelandMember 2018-01-01 2018-06-30 0001520262 us-gaap:OtherAssetsMember alks:FountainHealthcarePartnersIiLpOfIrelandMember 2018-12-31 0001520262 us-gaap:FairValueMeasurementsRecurringMember 2019-06-30 0001520262 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2019-06-30 0001520262 us-gaap:USGovernmentAgenciesDebtSecuritiesMember us-gaap:FairValueMeasurementsRecurringMember 2019-06-30 0001520262 us-gaap:USGovernmentAgenciesDebtSecuritiesMember us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2019-06-30 0001520262 us-gaap:USGovernmentAgenciesDebtSecuritiesMember us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2019-06-30 0001520262 us-gaap:CorporateDebtSecuritiesMember us-gaap:FairValueMeasurementsRecurringMember 2019-06-30 0001520262 us-gaap:CorporateDebtSecuritiesMember us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2019-06-30 0001520262 us-gaap:ForeignGovernmentDebtSecuritiesMember us-gaap:FairValueMeasurementsRecurringMember 2019-06-30 0001520262 us-gaap:ForeignGovernmentDebtSecuritiesMember us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2019-06-30 0001520262 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2019-06-30 0001520262 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2019-06-30 0001520262 us-gaap:FairValueMeasurementsRecurringMember 2018-12-31 0001520262 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2018-12-31 0001520262 us-gaap:USGovernmentAgenciesDebtSecuritiesMember us-gaap:FairValueMeasurementsRecurringMember 2018-12-31 0001520262 us-gaap:USGovernmentAgenciesDebtSecuritiesMember us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2018-12-31 0001520262 us-gaap:USGovernmentAgenciesDebtSecuritiesMember us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2018-12-31 0001520262 us-gaap:CorporateDebtSecuritiesMember us-gaap:FairValueMeasurementsRecurringMember 2018-12-31 0001520262 us-gaap:CorporateDebtSecuritiesMember us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2018-12-31 0001520262 us-gaap:CorporateDebtSecuritiesMember us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2018-12-31 0001520262 us-gaap:ForeignGovernmentDebtSecuritiesMember us-gaap:FairValueMeasurementsRecurringMember 2018-12-31 0001520262 us-gaap:ForeignGovernmentDebtSecuritiesMember us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2018-12-31 0001520262 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2018-12-31 0001520262 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2018-12-31 0001520262 alks:FairValueOfContingentConsiderationMember 2019-01-01 2019-06-30 0001520262 us-gaap:WarrantMember 2019-01-01 2019-06-30 0001520262 alks:RecroPharmaIncMember 2019-01-01 2019-03-31 0001520262 alks:RecroPharmaIncMember 2019-04-01 2019-06-30 0001520262 alks:RecroPharmaIncMember 2019-01-01 2019-06-30 0001520262 alks:RecroPharmaIncMember 2019-06-30 alks:Milestone alks:item 0001520262 us-gaap:MeasurementInputDiscountRateMember alks:RecroPharmaIncMember us-gaap:ScenarioForecastMember 2020-09-30 0001520262 us-gaap:MeasurementInputDiscountRateMember alks:FutureRoyaltiesMember 2019-06-30 0001520262 alks:RecroPharmaIncMember srt:MaximumMember 2019-01-01 2019-06-30 0001520262 us-gaap:MeasurementInputDiscountRateMember alks:ValuationTechniqueRealOptionsMember 2019-06-30 0001520262 alks:RecroPharmaIncMember 2018-12-31 0001520262 alks:RecroPharmaIncMember 2018-04-01 2018-06-30 0001520262 alks:RecroPharmaIncMember 2018-01-01 2018-06-30 0001520262 us-gaap:LandMember 2019-06-30 0001520262 us-gaap:LandMember 2018-12-31 0001520262 us-gaap:BuildingAndBuildingImprovementsMember 2019-06-30 0001520262 us-gaap:BuildingAndBuildingImprovementsMember 2018-12-31 0001520262 alks:FurnitureFixtureAndEquipmentMember 2019-06-30 0001520262 alks:FurnitureFixtureAndEquipmentMember 2018-12-31 0001520262 us-gaap:LeaseholdImprovementsMember 2019-06-30 0001520262 us-gaap:LeaseholdImprovementsMember 2018-12-31 0001520262 us-gaap:ConstructionInProgressMember 2019-06-30 0001520262 us-gaap:ConstructionInProgressMember 2018-12-31 0001520262 us-gaap:LicensingAgreementsMember 2019-01-01 2019-06-30 0001520262 alks:NanoCrystalTechnologyMember 2019-01-01 2019-06-30 0001520262 alks:OCRTechnologyMember 2019-01-01 2019-06-30 0001520262 us-gaap:LicensingAgreementsMember 2019-06-30 0001520262 alks:NanoCrystalTechnologyMember 2019-06-30 0001520262 alks:OCRTechnologyMember 2019-06-30 0001520262 us-gaap:LicensingAgreementsMember 2018-12-31 0001520262 alks:NanoCrystalTechnologyMember 2018-12-31 0001520262 alks:OCRTechnologyMember 2018-12-31 utr:sqft 0001520262 alks:CorporateOfficeAndAdministrativeSpaceExpireIn2021Member stpr:MA 2019-01-01 alks:Option 0001520262 alks:CorporateOfficeAndAdministrativeSpaceExpireIn2021Member stpr:MA 2019-01-01 2019-01-01 0001520262 alks:CorporateOfficeAndAdministrativeSpaceExpireIn2020Member stpr:MA 2019-01-01 0001520262 alks:CorporateOfficeAndAdministrativeSpaceExpireIn2020Member stpr:MA 2019-01-01 2019-01-01 0001520262 alks:CorporateOfficeAndAdministrativeSpaceExpireIn2022Member country:IE 2019-01-01 0001520262 alks:CorporateOfficeAndAdministrativeSpaceExpireIn2022Member country:IE 2019-01-01 2019-01-01 0001520262 alks:CorporateOfficeAndAdministrativeSpaceExpireInTwoThousandTwentyNineMember stpr:WA 2019-01-01 0001520262 alks:CorporateOfficeAndAdministrativeSpaceExpireInTwoThousandTwentyNineMember stpr:WA 2019-01-01 2019-01-01 alks:lease 0001520262 2018-03-01 2018-03-31 0001520262 alks:TwentyTwentyThreeTermLoansMember 2019-06-30 0001520262 alks:TwentyTwentyThreeTermLoansMember 2018-12-31 0001520262 alks:TermLoanB1Member 2016-10-12 2016-10-12 0001520262 alks:TwentyTwentyThreeTermLoansMember 2018-03-27 2019-03-31 0001520262 alks:TermLoanB1Member 2019-01-01 2019-06-30 0001520262 alks:TwentyTwentyThreeTermLoansMember 2019-01-01 2019-06-30 0001520262 alks:TermLoanB1Member us-gaap:LondonInterbankOfferedRateLIBORMember 2018-01-01 2018-03-26 0001520262 alks:TwentyTwentyThreeTermLoansMember us-gaap:LondonInterbankOfferedRateLIBORMember 2018-03-27 2019-03-31 0001520262 srt:MinimumMember 2019-01-01 2019-03-31 alks:Lender 0001520262 us-gaap:InterestExpenseMember 2018-01-01 2018-03-31 0001520262 us-gaap:FairValueInputsLevel2Member 2019-06-30 0001520262 us-gaap:FairValueInputsLevel2Member 2018-12-31 0001520262 us-gaap:CostOfSalesMember 2019-04-01 2019-06-30 0001520262 us-gaap:CostOfSalesMember 2018-04-01 2018-06-30 0001520262 us-gaap:CostOfSalesMember 2019-01-01 2019-06-30 0001520262 us-gaap:CostOfSalesMember 2018-01-01 2018-06-30 0001520262 us-gaap:ResearchAndDevelopmentExpenseMember 2019-04-01 2019-06-30 0001520262 us-gaap:ResearchAndDevelopmentExpenseMember 2018-04-01 2018-06-30 0001520262 us-gaap:ResearchAndDevelopmentExpenseMember 2019-01-01 2019-06-30 0001520262 us-gaap:ResearchAndDevelopmentExpenseMember 2018-01-01 2018-06-30 0001520262 us-gaap:SellingGeneralAndAdministrativeExpensesMember 2019-04-01 2019-06-30 0001520262 us-gaap:SellingGeneralAndAdministrativeExpensesMember 2018-04-01 2018-06-30 0001520262 us-gaap:SellingGeneralAndAdministrativeExpensesMember 2019-01-01 2019-06-30 0001520262 us-gaap:SellingGeneralAndAdministrativeExpensesMember 2018-01-01 2018-06-30 0001520262 alks:InventoryMember 2019-01-01 2019-06-30 0001520262 alks:InventoryMember 2018-01-01 2018-12-31 0001520262 alks:PerformanceBasedRestrictedStockUnitsMember 2019-01-01 2019-06-30 0001520262 alks:PerformanceBasedRestrictedStockUnitsMember 2019-06-30 0001520262 alks:PerformanceBasedRestrictedStockUnitsMember 2018-12-01 2018-12-31 0001520262 alks:PerformanceBasedRestrictedStockUnitsMember us-gaap:CostOfSalesMember 2018-12-01 2018-12-31 0001520262 alks:PerformanceBasedRestrictedStockUnitsMember us-gaap:ResearchAndDevelopmentExpenseMember 2018-12-01 2018-12-31 0001520262 alks:PerformanceBasedRestrictedStockUnitsMember us-gaap:SellingGeneralAndAdministrativeExpensesMember 2018-12-01 2018-12-31 0001520262 us-gaap:EmployeeStockOptionMember 2019-04-01 2019-06-30 0001520262 us-gaap:EmployeeStockOptionMember 2018-04-01 2018-06-30 0001520262 us-gaap:EmployeeStockOptionMember 2019-01-01 2019-06-30 0001520262 us-gaap:EmployeeStockOptionMember 2018-01-01 2018-06-30 0001520262 us-gaap:RestrictedStockUnitsRSUMember 2019-04-01 2019-06-30 0001520262 us-gaap:RestrictedStockUnitsRSUMember 2018-04-01 2018-06-30 0001520262 us-gaap:RestrictedStockUnitsRSUMember 2019-01-01 2019-06-30 0001520262 us-gaap:RestrictedStockUnitsRSUMember 2018-01-01 2018-06-30 alks:Notice alks:Filer

 

For support.

 

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

Form 10-Q

 

(Mark One)

 

 

QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

 

For the quarterly period ended June 30, 2019

 

OR

 

 

TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

 

Commission File Number 001-35299

ALKERMES PUBLIC LIMITED COMPANY

(Exact name of registrant as specified in its charter)

 

 

 

 

Ireland

 

98-1007018

(State or other jurisdiction of incorporation or organization)

 

(I.R.S. Employer Identification No.)

 

Connaught House

1 Burlington Road

Dublin 4Ireland D04 C5Y6

(Address of principal executive offices)

 

+ 353-1-772-8000

(Registrant’s telephone number, including area code)

 

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class

 

Trading Symbol(s)

 

Name of each exchange on which registered

Ordinary shares, $0.01 par value

 

ALKS

 

Nasdaq Global Select Market

 

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes   No 

 

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§ 232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes   No 

 

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

 

 

 

 

Large accelerated filer

 

Accelerated filer

Non-accelerated filer

 

Smaller reporting company

 

 

Emerging growth company

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.

 

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act):  Yes   No 

 

The number of the registrant’s ordinary shares, $0.01 par value, outstanding as of July 22, 2019 was 157,130,612 shares.

 

 

 

 

 

 


 

ALKERMES PLC AND SUBSIDIARIES

QUARTERLY REPORT ON FORM 10-Q

FOR THE QUARTERLY PERIOD ENDED JUNE 30, 2019

 

 

 

 

 

Page No.

PART I - FINANCIAL INFORMATION

 

Item 1.

Condensed Consolidated Financial Statements (unaudited):

 

 

Condensed Consolidated Balance Sheets — June 30, 2019 and December 31, 2018

5

 

Condensed Consolidated Statements of Operations and Comprehensive Loss — For the Three and Six Months Ended June 30, 2019 and 2018

6

 

Condensed Consolidated Statements of Cash Flows — For the Six Months Ended June 30, 2019 and 2018

7

 

Condensed Consolidated Statements of Shareholders’ Equity — For the Three and Six Months Ended June 30, 2019 and 2018

8

 

Notes to Condensed Consolidated Financial Statements

10

Item 2.

Management’s Discussion and Analysis of Financial Condition and Results of Operations

25

Item 3.

Quantitative and Qualitative Disclosures about Market Risk

38

Item 4.

Controls and Procedures

38

 

 

PART II - OTHER INFORMATION

 

Item 1.

Legal Proceedings

39

Item 1A.

Risk Factors

39

Item 2.

Unregistered Sales of Equity Securities and Use of Proceeds

39

Item 5.

Other Information

39

Item 6.

Exhibits

40

Signatures

41

 

2


 

Cautionary Note Concerning Forward-Looking Statements

This document contains and incorporates by reference “forward‑looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended (the “Securities Act”), and Section 21E of the Securities Exchange Act of 1934, as amended (the “Exchange Act”). In some cases, these statements can be identified by the use of forward‑looking terminology such as “may,” “will,” “could,” “should,” “would,” “expect,” “anticipate,” “continue,” “believe,” “plan,” “estimate,” “intend,” or other similar words. These statements discuss future expectations and contain projections of results of operations or of financial condition, or state trends and known uncertainties or other forward‑looking information. Forward-looking statements in this Quarterly Report on Form 10-Q (“Form 10-Q”) include, without limitation, statements regarding:

 

our expectations regarding our financial performance, including revenues, expenses, gross margins, liquidity, capital expenditures and income taxes;

 

our expectations regarding our products, including those expectations related to product development, regulatory filings, regulatory approvals and regulatory timelines, therapeutic and commercial scope and potential, and the costs and expenses related to such activities;

 

our expectations regarding the initiation, timing and results of clinical trials of our products;

 

our expectations regarding the competitive landscape, and changes therein, related to our products, including competition from generic forms of our products or competitive products and competitive development programs;

 

our expectations regarding the financial impact of currency exchange rate fluctuations and valuations;

 

our expectations regarding future amortization of intangible assets;

 

our expectations regarding our collaborations, licensing arrangements and other significant agreements with third parties relating to our products, including our development programs;

 

our expectations regarding the impact of new legislation, rules, regulations and the adoption of new accounting pronouncements;

 

our expectations regarding near‑term changes in the nature of our market risk exposures or in management’s objectives and strategies with respect to managing such exposures;

 

our ability to comply with restrictive covenants of our indebtedness and our ability to fund our debt service obligations;

 

our expectations regarding future capital requirements and capital expenditures and our ability to finance our operations and capital requirements;

 

our expectations regarding the timing, outcome and impact of administrative, regulatory, legal and other proceedings related to our patents, other proprietary and intellectual property (“IP”) rights, and our products; and

 

other factors discussed elsewhere in this Form 10-Q.

Actual results might differ materially from those expressed or implied by these forward-looking statements because these forward-looking statements are subject to risks, assumptions and uncertainties. You are cautioned not to place undue reliance on forward-looking statements, which speak only as of the date of this Form 10-Q. All subsequent written and oral forward-looking statements concerning the matters addressed in this Form 10-Q and attributable to us or any person acting on our behalf are expressly qualified in their entirety by the cautionary statements contained or referred to in this section. Except as required by applicable law or regulation, we do not undertake any obligation to update publicly or revise any forward-looking statements, whether as a result of new information, future events or otherwise. In light of these risks, assumptions and uncertainties, the forward-looking events discussed in this Form 10-Q might not occur. For more information regarding the risks, assumptions and uncertainties of our business, see “Part I, Item 1A—Risk Factors” in our Annual Report on Form 10-K for the year ended December 31, 2018 (the “Annual Report”).

3


 

This Form 10-Q includes data that we obtained from industry publications and third-party research, surveys and studies. Industry publications and third-party research, surveys and studies generally indicate that their information has been obtained from sources believed to be reliable, although they do not guarantee the accuracy or completeness of such information. This Form 10-Q also includes data based on our own internal estimates and research. Our internal estimates and research have not been verified by any independent source, and, while we believe the industry publications and third-party research, surveys and studies are reliable, we have not independently verified such data. Such third-party data and our internal estimates and research are necessarily subject to a high degree of uncertainty and risk due to a variety of factors, including those described in “Part I, Item 1A—Risk Factors” in our Annual Report and in subsequent reports filed with the United States (“U.S.”) Securities and Exchange Commission (the “SEC”). These and other factors could cause our results to differ materially from those expressed in this Form 10-Q.

Note Regarding Company and Product References

Alkermes plc (as used in this report, together with our subsidiaries, “Alkermes,” the “Company,” “us,” “we” and “our”) is a fully integrated, global biopharmaceutical company that applies its scientific expertise and proprietary technologies to research, develop and commercialize, both with partners and on its own, pharmaceutical products that are designed to address unmet medical needs of patients in major therapeutic areas. We have a diversified portfolio of commercial drug products and a clinical pipeline of product candidates focused on central nervous system (“CNS”) disorders such as schizophrenia, depression, addiction and multiple sclerosis (“MS”), and oncology. Except as otherwise suggested by the context, (a) references to “products” or “our products” in this Form 10-Q include our marketed products, marketed products using our proprietary technologies, our product candidates, and product candidates using our proprietary technologies, (b) references to the “biopharmaceutical industry” in this Form 10-Q are intended to include reference to the “biotechnology industry” and/or the “pharmaceutical industry” and (c) references in this Form 10-Q to “licensees” are used interchangeably with references to “partners.”

Note Regarding Trademarks

We are the owner of various U.S. federal trademark registrations (“®”) and other trademarks (“TM”), including ALKERMES®, ARISTADA®, ARISTADA INITIO®, LinkeRx®, NanoCrystal®, VIVITROL® and VUMERITYTM.

The following are trademarks of the respective companies listed: AMPYRA® and FAMPYRA®—Acorda Therapeutics, Inc. (“Acorda”); INVEGA SUSTENNA®, INVEGA TRINZA®, TREVICTA®, XEPLION®, and RISPERDAL CONSTA®—Johnson & Johnson (or its affiliates); TECFIDERA®—Biogen MA Inc. (together with its affiliates, “Biogen”); and ZYPREXA®Eli Lilly & Company. Other trademarks, trade names and service marks appearing in this Form 10-Q are the property of their respective owners. Solely for convenience, the trademarks and trade names in this Form 10-Q are referred to without the ® and TM symbols, but such references should not be construed as any indicator that their respective owners will not assert, to the fullest extent under applicable law, their rights thereto.

4


 

PART I. FINANCIAL INFORMATION

Item 1. Condensed Consolidated Financial Statements:

ALKERMES PLC AND SUBSIDIARIES

CONDENSED CONSOLIDATED BALANCE SHEETS

(unaudited)

 

 

 

June 30, 2019

 

December 31, 2018

 

 

(In thousands, except share and per share amounts)

ASSETS

 

 

 

 

CURRENT ASSETS:

 

 

 

 

Cash and cash equivalents

 

$195,954

 

$266,762

Investments—short-term

 

374,340

 

272,533

Receivables, net

 

261,226

 

292,223

Contract assets

 

12,690

 

8,230

Inventory

 

94,780

 

90,196

Prepaid expenses and other current assets

 

55,607

 

53,308

Total current assets

 

994,597

 

983,252

PROPERTY, PLANT AND EQUIPMENT, NET

 

326,230

 

309,987

INTANGIBLE ASSETS, NET

 

170,986

 

191,001

INVESTMENTS—LONG-TERM

 

23,299

 

80,744

GOODWILL

 

92,873

 

92,873

CONTINGENT CONSIDERATION

 

26,100

 

65,200

RIGHT-OF-USE ASSETS

 

15,911

 

DEFERRED TAX ASSETS

 

86,894

 

85,807

OTHER ASSETS

 

14,861

 

16,143

TOTAL ASSETS

 

$1,751,751

 

$1,825,007

LIABILITIES AND SHAREHOLDERS’ EQUITY

 

 

 

 

CURRENT LIABILITIES:

 

 

 

 

Accounts payable and accrued expenses

 

$320,490

 

$333,762

Contract liabilities—short-term

 

2,103

 

3,169

Operating lease liabilities—short-term

 

8,710

 

Long-term debt—short-term

 

2,843

 

2,843

Total current liabilities

 

334,146

 

339,774

LONG-TERM DEBT

 

275,381

 

276,465

OTHER LONG-TERM LIABILITIES

 

30,571

 

27,958

OPERATING LEASE LIABILITIES—LONG-TERM

 

8,864

 

CONTRACT LIABILITIES—LONG-TERM

 

11,621

 

9,525

Total liabilities

 

660,583

 

653,722

COMMITMENTS AND CONTINGENT LIABILITIES (Note 14)

 

 

 

 

SHAREHOLDERS’ EQUITY:

 

 

 

 

Preferred shares, par value, $0.01 per share; 50,000,000 shares authorized; zero issued and outstanding at June 30, 2019 and December 31, 2018, respectively

 

 

Ordinary shares, par value, $0.01 per share; 450,000,000 shares authorized; 159,796,116 and 158,180,833 shares issued; 157,096,873 and 155,757,344 shares outstanding at June 30, 2019 and December 31, 2018, respectively

 

1,595

 

1,579

Treasury shares, at cost (2,699,243 and 2,423,489 shares at June 30, 2019 and December 31, 2018, respectively)

 

(118,143)

 

(108,969)

Additional paid-in capital

 

2,533,086

 

2,467,323

Accumulated other comprehensive loss

 

(1,614)

 

(3,280)

Accumulated deficit

 

(1,323,756)

 

(1,185,368)

Total shareholders’ equity

 

1,091,168

 

1,171,285

TOTAL LIABILITIES AND SHAREHOLDERS’ EQUITY

 

$1,751,751

 

$1,825,007

 

The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.

5


 

ALKERMES PLC AND SUBSIDIARIES

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS

(unaudited)

 

 

 

Three Months Ended

 

 

Six Months Ended

 

 

 

June 30,

 

 

June 30,

 

 

 

2019

 

 

2018

 

 

2019

 

 

2018

 

 

 

(In thousands, except per share amounts)

 

 

 

 

 

 

 

 

 

REVENUES:

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Manufacturing and royalty revenues

 

$

127,897

 

 

$

128,241

 

 

$

236,812

 

 

$

242,842

 

Product sales, net

 

 

136,635

 

 

 

109,807

 

 

 

236,116

 

 

 

201,649

 

Research and development revenue

 

 

14,340

 

 

 

18,344

 

 

 

29,046

 

 

 

37,051

 

License revenue

 

 

1,000

 

 

 

48,250

 

 

 

1,000

 

 

 

48,250

 

Total revenues

 

 

279,872

 

 

 

304,642

 

 

 

502,974

 

 

 

529,792

 

EXPENSES:

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Cost of goods manufactured and sold (exclusive of amortization of acquired intangible assets shown below)

 

 

46,223

 

 

 

43,417

 

 

 

91,584

 

 

 

87,893

 

Research and development

 

 

104,435

 

 

 

106,823

 

 

 

207,005

 

 

 

215,169

 

Selling, general and administrative

 

 

155,075

 

 

 

138,257

 

 

 

296,295

 

 

 

256,404

 

Amortization of acquired intangible assets

 

 

10,062

 

 

 

16,247

 

 

 

20,014

 

 

 

32,316

 

Total expenses

 

 

315,795

 

 

 

304,744

 

 

 

614,898

 

 

 

591,782

 

OPERATING LOSS

 

 

(35,923

)

 

 

(102

)

 

 

(111,924

)

 

 

(61,990

)

OTHER EXPENSE, NET:

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Interest income

 

 

3,706

 

 

 

1,900

 

 

 

7,276

 

 

 

3,386

 

Interest expense

 

 

(3,520

)

 

 

(3,126

)

 

 

(7,020

)

 

 

(8,614

)

Change in the fair value of contingent consideration

 

 

(6,500

)

 

 

(19,600

)

 

 

(29,100

)

 

 

(21,500

)

Other income (expense), net

 

 

1,851

 

 

 

(3,517

)

 

 

130

 

 

 

(2,725

)

Total other expense, net

 

 

(4,463

)

 

 

(24,343

)

 

 

(28,714

)

 

 

(29,453

)

LOSS BEFORE INCOME TAXES

 

 

(40,386

)

 

 

(24,445

)

 

 

(140,638

)

 

 

(91,443

)

INCOME TAX PROVISION (BENEFIT)

 

 

1,604

 

 

 

8,204

 

 

 

(2,250

)

 

 

3,711

 

NET LOSS

 

$

(41,990

)

 

$

(32,649

)

 

$

(138,388

)

 

$

(95,154

)

LOSS PER ORDINARY SHARE:

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Basic and diluted

 

$

(0.27

)

 

$

(0.21

)

 

$

(0.88

)

 

$

(0.61

)

WEIGHTED AVERAGE NUMBER OF ORDINARY SHARES OUTSTANDING:

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Basic and diluted

 

 

156,991

 

 

 

155,176

 

 

 

156,665

 

 

 

154,802

 

COMPREHENSIVE LOSS:

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Net loss

 

$

(41,990

)

 

$

(32,649

)

 

$

(138,388

)

 

$

(95,154

)

Holding gain (loss), net of a tax provision (benefit) of $265, $47, $494 and $(53), respectively

 

 

896

 

 

 

148

 

 

 

1,666

 

 

 

(188

)

COMPREHENSIVE LOSS

 

$

(41,094

)

 

$

(32,501

)

 

$

(136,722

)

 

$

(95,342

)

 

The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.

6


 

ALKERMES PLC AND SUBSIDIARIES

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS

(unaudited)

 

 

 

Six Months Ended

 

 

 

June 30,

 

 

 

2019

 

 

2018

 

 

 

(In thousands)

 

CASH FLOWS FROM OPERATING ACTIVITIES:

 

 

 

 

 

 

 

 

Net loss

 

$

(138,388

)

 

$

(95,154

)

Adjustments to reconcile net loss to cash flows from operating activities:

 

 

 

 

 

 

 

 

Depreciation and amortization

 

 

39,556

 

 

 

51,491

 

Share-based compensation expense

 

 

52,861

 

 

 

50,975

 

Deferred income taxes

 

 

(2,401

)

 

 

3,368

 

Change in the fair value of contingent consideration

 

 

29,100

 

 

 

21,500

 

Loss on debt refinancing

 

 

 

 

 

2,298

 

Payment made for debt refinancing

 

 

 

 

 

(2,251

)

Other non-cash charges

 

 

675

 

 

 

1,398

 

Changes in assets and liabilities:

 

 

 

 

 

 

 

 

Receivables

 

 

30,996

 

 

 

(21,640

)

Contract assets

 

 

(4,460

)

 

 

(5,471

)

Inventory

 

 

(3,928

)

 

 

(2,082

)

Prepaid expenses and other assets

 

 

737

 

 

 

(1,615

)

Right-of-use assets

 

 

4,229

 

 

 

 

Accounts payable and accrued expenses

 

 

(9,918

)

 

 

(2,624

)

Contract liabilities

 

 

1,030

 

 

 

1,343

 

Operating lease liabilities

 

 

(4,593

)

 

 

 

Other long-term liabilities

 

 

3,539

 

 

 

3,752

 

Cash flows (used in) provided by operating activities

 

 

(965

)

 

 

5,288

 

CASH FLOWS FROM INVESTING ACTIVITIES:

 

 

 

 

 

 

 

 

Additions of property, plant and equipment

 

 

(39,542

)

 

 

(35,420

)

Proceeds from the sale of equipment

 

 

291

 

 

 

423

 

Proceeds from contingent consideration

 

 

10,000

 

 

 

 

Purchases of investments

 

 

(121,809

)

 

 

(138,644

)

Sales and maturities of investments

 

 

79,104

 

 

 

133,101

 

Cash flows used in investing activities

 

 

(71,956

)

 

 

(40,540

)

CASH FLOWS FROM FINANCING ACTIVITIES:

 

 

 

 

 

 

 

 

Proceeds from the issuance of ordinary shares under share-based compensation arrangements

 

 

12,608

 

 

 

17,000

 

Employee taxes paid related to net share settlement of equity awards

 

 

(9,074

)

 

 

(15,742

)

Principal payments of long-term debt

 

 

(1,421

)

 

 

(710

)

Payment made for debt refinancing

 

 

 

 

 

(743

)

Cash flows provided by (used in) financing activities

 

 

2,113

 

 

 

(195

)

NET DECREASE IN CASH AND CASH EQUIVALENTS

 

 

(70,808

)

 

 

(35,447

)

CASH AND CASH EQUIVALENTS—Beginning of period

 

 

266,762

 

 

 

191,296

 

CASH AND CASH EQUIVALENTS—End of period

 

$

195,954

 

 

$

155,849

 

SUPPLEMENTAL CASH FLOW DISCLOSURE:

 

 

 

 

 

 

 

 

Non-cash investing and financing activities:

 

 

 

 

 

 

 

 

Purchased capital expenditures included in accounts payable and accrued expenses

 

$

2,994

 

 

$

7,246

 

 

The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.

 

 

7


 

ALKERMES PLC AND SUBSIDIARIES

CONDENSED CONSOLIDATED STATEMENTS OF SHAREHOLDERS’ EQUITY

(unaudited)

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Accumulated

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Additional

 

 

Other

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Ordinary Shares

 

 

Paid-In

 

 

Comprehensive

 

 

Accumulated

 

 

Treasury Stock

 

 

 

 

 

 

 

Shares

 

 

Amount

 

 

Capital

 

 

Loss

 

 

Deficit

 

 

Shares

 

 

Amount

 

 

Total

 

 

 

(In thousands, except share data)

 

BALANCE — December 31, 2018

 

 

158,180,833

 

 

$

1,579

 

 

$

2,467,323

 

 

$

(3,280

)

 

$

(1,185,368

)

 

 

(2,423,489

)

 

$

(108,969

)

 

$

1,171,285

 

Issuance of ordinary shares under employee stock plans

 

 

656,352

 

 

 

7

 

 

 

10,547

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

10,554

 

Receipt of Alkermes' shares for the exercise of stock options or to satisfy minimum tax withholding obligations related to share-based awards

 

 

740,689

 

 

 

7

 

 

 

93

 

 

 

 

 

 

 

 

 

(269,357

)

 

 

(8,980

)

 

 

(8,880

)

Share-based compensation expense

 

 

 

 

 

 

 

 

24,810

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

24,810

 

Unrealized gain on marketable securities, net of tax provision of $229

 

 

 

 

 

 

 

 

 

 

 

770

 

 

 

 

 

 

 

 

 

 

 

 

770

 

Net loss

 

 

 

 

 

 

 

 

 

 

 

 

 

 

(96,398

)

 

 

 

 

 

 

 

 

(96,398

)

BALANCE — March 31, 2019

 

 

159,577,874

 

 

$

1,593

 

 

$

2,502,773

 

 

$

(2,510

)

 

$

(1,281,766

)

 

 

(2,692,846

)

 

$

(117,949

)

 

$

1,102,141

 

Issuance of ordinary shares under employee stock plans

 

 

197,953

 

 

2

 

 

 

2,052

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

2,054

 

Receipt of Alkermes' shares for the purchase of stock options or to satisfy minimum tax withholding obligations related to share-based awards

 

 

20,289

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

(6,397

)

 

 

(194

)

 

 

(194

)

Share-based compensation expense

 

 

 

 

 

 

 

 

28,261

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

28,261

 

Unrealized loss on marketable securities, net of tax provision of $265

 

 

 

 

 

 

 

 

 

 

 

896

 

 

 

 

 

 

 

 

 

 

 

 

896

 

Net loss

 

 

 

 

 

 

 

 

 

 

 

 

 

 

(41,990

)

 

 

 

 

 

 

 

 

(41,990

)

BALANCE — June 30, 2019

 

 

159,796,116

 

 

$

1,595

 

 

$

2,533,086

 

 

$

(1,614

)

 

$

(1,323,756

)

 

 

(2,699,243

)

 

$

(118,143

)

 

$

1,091,168

 

 

8